Press Releases
CAESAREA, Israel –(BUSINESS WIRE)– Mazor Robotics Ltd. (TASE: MZOR; NASDAQCM: MZOR), the developer of Renaissance®, an innovative surgical guidance system and its complementary products, announced today that a hospital in the southeastern United States has purchased its first Renaissance system. The hospital that purchased the system is an integrated healthcare delivery system that provides care from birth to hospice and for more than 90 years has earned a reputation for technological excellence throughout the Southeast.
“We are excited from the continued adoption of the Mazor Robotics Renaissance system by spine surgeons and health providers in the United States and particularly in the south east of the United States,” commented Ori Hadomi, Chief Executive Officer, “There are now 11 Renaissance systems in the Southeastern United States providing surgeons and their patients a highly accurate and safe approach to spine surgery.”
About Mazor
Mazor Robotics (TASE: MZOR; NASDAQGM: MZOR) believes in healing through innovation by developing and introducing revolutionary robotic-based technology and products aimed at redefining the gold standard of quality care. Mazor Robotics Renaissance® Guidance System enables surgeons to conduct spine and brain procedures in a more accurate and secure manner. For more information, please visit www.MazorRobotics.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other securities laws. Any statements in this release about future expectations, plans or prospects for the Company, including without limitation, statements regarding the expectations for growth in system sales and recurring revenue, the Company’s expected sales in 2016, and other statements containing the words “believes,” “anticipates,” “plans,” “expects,” “will” and similar expressions are forward-looking statements. These statements are only predictions based on Mazor’s current expectations and projections about future events. There are important factors that could cause Mazor’s actual results, level of activity, performance or achievements to differ materially from the results, level of activity, performance or achievements expressed or implied by the forward-looking statements. Those factors include, but are not limited to, the impact of general economic conditions, competitive products, product demand and market acceptance risks, reliance on key strategic alliances, fluctuations in operating results, and other factors indicated in Mazor’s filings with the Securities and Exchange Commission (SEC) including those discussed under the heading “Risk Factors” in Mazor’s annual report on Form 20-F filed with the SEC on April 29, 2015 and in subsequent filings with the SEC. For more details, refer to Mazor’s SEC filings. Mazor undertakes no obligation to update forward-looking statements to reflect subsequent occurring events or circumstances, or to changes in our expectations, except as may be required by law.
U.S. Contacts: EVC Group
Michael Polyviou/Doug Sherk – Investors
mpolyviou@evcgroup.com; dsherk@evcgroup.com
212.850.6020; 646-445-4800
David Schemelia – Media
646.201.5431
Latest Tweet
Mazor #CoreTechnology can help you produce consistent results that lead to improved clinical outcomes. Get more inf… https://t.co/LJDbcI17O1